XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Accounting Policies, Revenue Recognition (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2021
USD ($)
Feb. 28, 2017
USD ($)
PerformanceObligation
May 31, 2015
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2018
USD ($)
Jun. 30, 2018
Agreement
Jun. 30, 2021
USD ($)
PerformanceObligation
Jun. 30, 2020
USD ($)
Revenue Recognition [Abstract]                    
Number of performance obligations at inception of contract | PerformanceObligation                 1  
Revenue       $ 125,750   $ 145,537     $ 237,357 $ 278,905
Biogen [Member]                    
Revenue Recognition [Abstract]                    
Number of agreements | Agreement               2    
Biogen 2013 Strategic Neurology [Member] | ION541 [Member]                    
Revenue Recognition [Abstract]                    
Revenue $ 10,000     $ 10,000            
IONIS-FB-L for Complement-Mediated Diseases [Member]                    
Revenue Recognition [Abstract]                    
Upfront payment received             $ 75,000      
Biogen 2018 Strategic Neurology [Member]                    
Revenue Recognition [Abstract]                    
Milestone payment received and added to transaction price         $ 7,500          
AstraZeneca [Member] | ION455 [Member]                    
Revenue Recognition [Abstract]                    
Revenue         $ 30,000          
Bayer [Member]                    
Revenue Recognition [Abstract]                    
Upfront payment received     $ 100,000              
Bayer [Member]                    
Revenue Recognition [Abstract]                    
Upfront payment received   $ 75,000                
Number of separate performance obligations | PerformanceObligation   3                
Transaction price   $ 75,000